Llwytho...
Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury
A screen by Kost-Alimova et al.(1) suggests that the FDA-approved SYK inhibitor fostamatinib inhibits MUC1 in the respiratory tract and has the potential to treat serious outcomes of coronavirus COVID-19, including acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Cell Rep Med |
|---|---|
| Prif Awduron: | , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Elsevier
2020
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7670931/ https://ncbi.nlm.nih.gov/pubmed/33225317 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.xcrm.2020.100145 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|